FRAPS

NDA Partners Appoints Senior Global Regulatory Affairs Executive, Dr. Daniela Drago as Partner in the Firm

Retrieved on: 
Tuesday, April 4, 2023
CSL Vifor, RAPS, Medical school, Swiss Federal Institute of Technology, Swiss, Biozentrum University of Basel, University, Gene, Swiss Federal Institute of Aquatic Science and Technology, ETH, Biogen, CMC, Roche, George Washington University Hospital, Bausch, Regulatory science, History, Doctor of Philosophy, Associate, Bausch & Lomb, ECPM, MS, FRAPS, Partner, UCSF, Ophthalmology, School, Cell, Executive Committee, Drug development, American Society of Gene and Cell Therapy, University of Messina, Regulatory affairs, George Washington University, Neurology, Pharmaceutical medicine, Society, Pharmaceutical industry, Medicine, Chemistry

WASHINGTON, April 4, 2023 /PRNewswire-PRWeb/ -- NDA Partners' Vice President and General Manager, Eric Fish, announced today that Dr. Daniela Drago, a senior global regulatory affairs executive, has been appointed as Partner in the firm. Dr. Drago first worked as an Expert Consultant with NDA Partners in 2014 and formerly held senior global regulatory and medical affairs positions at Biogen, Roche, Vifor Pharma, Reckitt Benckiser, Aurion Biotech, and Bausch & Lomb.

Key Points: 
  • NDA Partners' Vice President and General Manager, Eric Fish, announced today that Dr. Daniela Drago, a senior global regulatory affairs executive, has been appointed as Partner in the firm.
  • Dr. Drago first worked as an Expert Consultant with NDA Partners in 2014 and formerly held senior global regulatory and medical affairs positions at Biogen, Roche, Vifor Pharma, Reckitt Benckiser, Aurion Biotech, and Bausch & Lomb.
  • WASHINGTON, April 4, 2023 /PRNewswire-PRWeb/ -- NDA Partners' Vice President and General Manager, Eric Fish, announced today that Dr. Daniela Drago , a senior global regulatory affairs executive, has been appointed as Partner in the firm.
  • Dr. Drago is a CMC and global regulatory affairs executive with a history of accomplishments spanning pharmaceutical, biotech, and academic roles.

1,700 Gather in Phoenix for RAPS Convergence 2022

Retrieved on: 
Wednesday, September 14, 2022
Practice, European Medicines Agency, Lunch, RAPS, FDA, Mallinckrodt, Publication, RAC, Medicines and Healthcare products Regulatory Agency, Mentorship, Learning, COO, Intelligence, Convergence, COVID, IVD, Compensation, Regulatory affairs, Health Canada, Yoga, Â, Research, GLOBE, Health, Thermo Fisher Scientific, Disagreement, Education, Medical device, Tutoring, Pharmaceutical industry, FRAPS

Phoenix, Sept. 14, 2022 (GLOBE NEWSWIRE) -- The Regulatory Affairs Professional Society (RAPS) concluded its annual RAPS Convergence in Phoenix on Tuesday, attracting 1,700 participants from 41 countries across five continents.

Key Points: 
  • Phoenix, Sept. 14, 2022 (GLOBE NEWSWIRE) -- The Regulatory Affairs Professional Society (RAPS) concluded its annual RAPS Convergence in Phoenix on Tuesday, attracting 1,700 participants from 41 countries across five continents.
  • In addition to the presentations, learning opportunities and exhibitor/sponsor innovation demonstrations, RAPS Convergence focused on bringing the global regulatory community together, said Bill McMoil, RAPS Executive Director and COO.
  • Weve talked about the pandemic, and weve talked about the lessons learned, said Megha Deviprasad Iyer, RAC, of Thermo Fisher Scientific and RAPS Convergence 2022 Planning Committee vice chair.
  • RAPS also launched the latest iteration of its RAPS Global Scope of Practice & Compensation Survey at the event on Tuesday.

Senior Global Regulatory Affairs Executive, Dr. Daniela Drago, Joins NDA Partners as Expert Consultant

Retrieved on: 
Wednesday, September 7, 2022
Swiss Federal Institute of Technology, University, Pharmaceutical medicine, Swiss, Pharmacokinetics, Ophthalmology, Program, Gene, Cell, ETH, Executive Committee, Biogen, Doctor of Philosophy, Associate, Bausch & Lomb, Medical school, American Society of Gene and Cell Therapy, Society, Bausch, University of Messina, Swiss Federal Institute of Aquatic Science and Technology, ECPM, Biozentrum University of Basel, CMC, School, Drug development, Neurology, Roche, Regulatory science, George Washington University, History, George Washington University School of Medicine & Health Sciences, Biotechnology, Regulatory affairs, University of California, San Francisco, UCSF, Toxicology, MS, RAPS, Vifor Pharma, USP, FRAPS, General manager, Medical device, Pharmaceutical industry, Medicine, Chemistry

WASHINGTON, Sept. 7, 2022 /PRNewswire-PRWeb/ -- NDA Partners' General Manager, Eric Fish, announced today that Dr. Daniela Drago, a senior global regulatory affairs executive, has joined the firm as an Expert Consultant. Dr. Drago is a regulatory affairs executive with a history of accomplishments spanning pharmaceutical, biotech, and academic roles. She has held senior global regulatory and medical affairs positions at Biogen, Roche, Vifor Pharma, Reckitt Benckiser, Aurion Biotech, and Bausch & Lomb. She was formerly an Associate Professor at George Washington University's School of Medicine where she redesigned and led the regulatory affairs program. Currently, she is an Adjunct Faculty for the University of California, San Francisco (UCSF), American Course on Drug Development and Regulatory Sciences (ACDRS), and the University of Basel, European Center of Pharmaceutical Medicine (ECPM).

Key Points: 
  • NDA Partners' General Manager, Eric Fish, announced today that Dr. Daniela Drago, a senior global regulatory affairs executive, has joined the firm as an Expert Consultant.
  • Dr. Drago has held senior global regulatory and medical affairs positions at Biogen, Roche, Vifor Pharma, Reckitt Benckiser, Aurion Biotech, and Bausch & Lomb.
  • WASHINGTON, Sept. 7, 2022 /PRNewswire-PRWeb/ -- NDA Partners' General Manager, Eric Fish, announced today that Dr. Daniela Drago , a senior global regulatory affairs executive, has joined the firm as an Expert Consultant.
  • She has held senior global regulatory and medical affairs positions at Biogen, Roche, Vifor Pharma, Reckitt Benckiser, Aurion Biotech, and Bausch & Lomb.

Life Edit Therapeutics Appoints Joy A. Cavagnaro to Its Scientific Advisory Board

Retrieved on: 
Wednesday, June 29, 2022
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Washington metropolitan area, FDA, University of North Carolina at Greensboro, Patient, LinkedIn, Engineering, Regulatory affairs, Edit, R, Society, SAB, Access, Center for Biologics Evaluation and Research, United States Air Force Scientific Advisory Board, Chapel Hill, Founder, Therapy, DABT, Gene editing, Drug discovery, RAC, RNA, Genome, Technology, Center, RAPS, SOT, University, Rgn, American College of Toxicology, Arnold, American College, Twitter, Duke University, Doctor of Philosophy, Pharmaceutical industry, Vaccine, FRAPS, Toxicology, Biochemistry, Research

Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation genome editing technologies and therapeutics, today announced the appointment of Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, to its Scientific Advisory Board (SAB).

Key Points: 
  • Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation genome editing technologies and therapeutics, today announced the appointment of Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, to its Scientific Advisory Board (SAB).
  • We are thrilled to welcome Joy to our Scientific Advisory Board as we rapidly advance our gene editing platform to harness the vast potential of our novel nucleases and base editors as therapeutics, said Mitchell Finer, Ph.D., Chief Executive Officer, Life Edit Therapeutics and President, R&D, ElevateBio.
  • Joys expertise in drug discovery and development will complement our esteemed Scientific Advisory Board slate, and collectively our advisors will continue to help Life Edit and our partners further therapeutic programs to address the tremendous unmet needs of genetically-defined diseases.
  • About Life Edit Therapeutics Inc.
    Life Edit Therapeutics, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the worlds largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors.

Alliance for Artificial Intelligence in Healthcare Elects New Board Leadership for 2022

Retrieved on: 
Wednesday, March 2, 2022
Doctor of Philosophy, Adoption, Leadership, Patient, Health Canada, Industry, European Medicines Agency, Regulatory affairs, Health, SVP, Roche, Director, Board of directors, Medicine, FDA, EMA, RAC, Vive, Board, Artificial intelligence, AI, Technology, GSK, Johnson & Johnson, Drug discovery, Medical device, Fine chemical, Management, FRAPS

BALTIMORE, March 2, 2022 /PRNewswire-PRWeb/ -- Alliance for Artificial Intelligence in Healthcare (AAIH), a 501(c)(4) non-profit advocacy and educational organization dedicated to promoting the development and implementation of AI in healthcare, has appointed a new slate of Board Members and Executive Officers for 2022.

Key Points: 
  • BALTIMORE, March 2, 2022 /PRNewswire-PRWeb/ -- Alliance for Artificial Intelligence in Healthcare (AAIH), a 501(c)(4) non-profit advocacy and educational organization dedicated to promoting the development and implementation of AI in healthcare, has appointed a new slate of Board Members and Executive Officers for 2022.
  • AAIH works globally with industry, academia, patient advocacy and government stakeholders to address key challenges and opportunities surrounding the adoption of AI in healthcare.
  • I am confident the incoming leadership will build on current efforts and spread our mission and vision," said Dr. Allgood.
  • The conference brings together healthcare industry leaders who are shaping tech-enabled healthcare and addressing key issues in digital health innovation, including AI/ML technologies.